本帖最后由 老马 于 2012-1-13 21:20 编辑 8 i7 x$ C6 J& Q
! j/ A; X7 S" F0 g% B
爱必妥和阿瓦斯丁的比较
. r2 j0 Y! m* e
: ^, i1 A8 W% w; {" O! f
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/5 n0 r0 q- M: D7 ?6 n+ s
) l8 T' T; n. `* b: g
6 | J! C# q" m
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
, y8 a6 P0 G- d2 \+ m5 P# o==================================================
* j8 U4 a( A" C& ?Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
- Y) a7 ?4 Y8 L# SPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.8 z* ^- ]; W* c3 G0 | D
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.3 Y1 q1 u H( B
|